2015年
- Shimoda S, Okubo M, Koga K, Sekigami T, Kawashima J, Kukidome D, Igata M, Ishii N, Shimakawa A, Matsumura T, Motoshima H, Furukawa N, Nishida K, Araki E. Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy. Endocr J 62:209-216, 2015.
- Fukuda K, Matsumura T, Senokuchi T, Ishii N, Kinoshita H, Yamada S, Murakami S, Nakao S, Motoshima H, Kondo T, Kukidome D, Kawasaki S, Kawada T, Nishikawa T, Araki E. Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor-γ activation. Biochem Biophys Res Commun 457:23-30, 2015.
- Nishikawa T, Brownlee M, Araki E. Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy. J Diabetes Invest 6:137-139, 2015
- Kukidome D, Nishikawa T, Sato M, Igata M, Kawashima J, Shimoda S, Matsui K, Obayashi K, Ando Y, Araki E. Measurement of small fibre pain threshold values for the early detection of diabetic polyneuropathy. Diabetic Medicine 33(1):62-69, 2015.
- Oyama K, Taniguchi J, Goto R, Matsui K. Remitting seronegative symmetrical synovitis with pitting edema syndrome in individuals with type 2 diabetes mellitus or impaired glucose tolerance. Diabetes Res Clin Pract. 110(1):e5-8, 2015.
- Araki E, Tanizawa Y, Tanaka Y, Taniguchi A, Koiwai K, Kim G, Salsali A, Woerle H.J, Broed U.C. Long-term treatment with empagliflozin as add-on to oral anti-diabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obesity & Metabolism 17(7): 665-674, 2015
- Kawashima J, Naoe H, Sasaki Y, Araki E. A rare case showing subacute thyroiditis-like symptoms with amyloid goiter after ani-tumor necrosis factor therapy. Endocrinology, Diabetes & Metabolism 2015, in press
- Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once weekly Efficacy and safety of once weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once daily insulin glargine in Japanese patients with type 2 diabetes: a randomised, open-label, phase 3, non-inferiority study. Diabetes Obesity & Metabolism 17(10):994-1002, 2015.
- Araki E, Kondo T, Kai H. Cellular stress response pathways and diabetes mellitus. Diabetol Int 6: 239-242, 2015.
